- Home
- FITBO vs HUMAW Comparison
FITBO vs HUMAW Comparison
Compare FITBO & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FITBO
Fifth Third Bancorp Depositary Shares each representing a 1/1000th ownership interest in a share of Non-Cumulative Perpetual Preferred Stock Series K
Current Price
Company Overview
Basic Information| Metric | FITBO | HUMAW |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | 18616 | 220 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FITBO | HUMAW |
|---|---|---|
| Price | $19.44 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.0K | 4.9K |
| Earning Date | N/A | 03-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.19 | $0.08 |
| 52 Week High | $22.80 | $1.02 |
Technical Indicators
Market Signals| Indicator | FITBO | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 51.61 |
| Support Level | $19.20 | $0.09 |
| Resistance Level | $19.85 | $0.15 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 11.75 | 78.26 |
Price Performance
Historical ComparisonAbout FITBO Fifth Third Bancorp Depositary Shares each representing a 1/1000th ownership interest in a share of Non-Cumulative Perpetual Preferred Stock Series K
Fifth Third Bancorp is a midsize regional bank in the US, with total assets of over $210 billion as of December 2025. The bank is set to close its acquisition of Comercia on Feb. 1, 2026. Headquartered in Cincinnati, Ohio, Fifth Third has a strong presence in the US Midwest and is currently expanding in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and Treasury management, wealth and asset management, and capital markets.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.